Details
Benefits:
- is the first and only medicine available in the US that is fully approved by the FDA to treat pituitary pars intermedia dysfunction (more commonly called PPID or equine Cushing's disease)
- for use in horses.
Human Warnings:
Not for use in humans. Keep this and all medications out of the reach of children. Prascend should not be administered by persons who have had adverse reactions to ergotamine or other ergot derivatives. Pregnant or lactating women should wear gloves when administering this product. It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when Prascend Tablets are split or crushed. Prascend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. Consult a physician in case of accidental ingestion by humans.
Treatment with Prascend may cause inappetance.
Contraindications: Prascend is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives.
Warnings: Do not use in horses intended for human consumption.
Precautions:
Treatment with Prascend may cause loss of appetite, lethargy, diarrhea, and other behavioral changes. The use of Prascend in breeding, pregnant, or lactating horses has not been evaluated. The pharmacologic action of pergolide mesylate suggests that it may interfere with reproductive functions such as lactation.
Prascend is approximately 90% associated with plasma proteins. Use caution if administering Prascend with other drugs that affect protein binding. Dopamine antagonists, such as neuroleptics (phenothiazines, domperidone) or metoclopramide, ordinarily should not be administered concurrently with Prascend (a dopamine agonist) since these agents may diminish the effectiveness of Prascend.
Storage:
Store at or below 25°C (77°F).
Instructions
Dosage and Administration:
It is important to follow your Veterinarian's prescription instructions for your pet.
Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when Prascend Tablets are split or crushed. Prascend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment see Table 1.
Table 1 Dosing Table
| Dosage |
Body weight | 2 mcg/kg | 4 mcg/kg |
136 - 340 kg 300 - 749 lb |
0.5 tablet |
1 tablet |
341 - 567 kg 750 - 1,249 lb |
1 tablet |
2 tablets |
136 - 340 kg 300 - 749 lb |
1.5 tablets |
3 tablets |
341 - 567 kg 750 - 1,249 lb |
2 tablets |
4 tablets |
Dosing should be titrated according to individual response to therapy to achieve the lowest effective dose. Dose titration is based on improvement in clinical signs associated with Pituitary Pars Intermedia Dysfunction PPID and/or improvement or normalization of endocrine tests for example, dexamethasone suppression test or endogenous ACTH test. If signs of dose intolerance develop, the dose should be decreased by half for 3 to 5 days and then titrated back up in 2 mcg/kg increments every 2 weeks until the desired effect is achieved.